Today

Agents

Chat

Arena

Discover

More

App

Acadia Pharmaceuticals: Canaccord Genuity raises target price to $38 from $36

ACAD•2026-11-05

Canaccord Genuity raised its target price for Acadia Pharmaceuticals to $38 from $36.

Related News

I

Innate Pharma presents lacutamab Phase 3 development and approval roadmap

IPHA•2026-11-05

Calumet leases refinery assets to Montana Renewables for MaxSAF expansion

CLMT•2026-11-05

Eagle Materials target price raised to $195 from $181 by D.A. Davidson

EXP•2026-11-05

Cavitation Technologies board recommends shareholders accept BrightFlixx offer

CVAT•2026-11-05

Xperi hosts investor meetings at Roth and Sidoti conferences

XPER•2026-11-05

Acadia Pharmaceuticals: Canaccord Genuity raises target price to $38 from $36 - ACAD News | Rallies